Tesaro Hit With Investor Suit Over $5B Merger Deal With GSK
A stockholder's proposed class action against cancer drug manufacturer Tesaro Inc. and its executives has alleged in Delaware federal court that a proposed $5.1 billion merger with British pharmaceutical company GlaxoSmithKline...To view the full article, register now.
Already a subscriber? Click here to view full article